https://www.selleckchem.com/pr....oducts/trastuzumab.h
BK virus (BKV) replication occurs frequently in kidney transplant recipients (KTR), potentially leading to BKV-associated nephropathy (BKVAN) and graft loss. Patients with high titers of BKV-neutralizing antibodies (NAbs) are protected against BKV replication, and intravenous immunoglobulin (IVIg) infusion can increase NAb titers. We investigated whether early IVIg administration prevents BKV replication in patients with low NAb titers ( less then 4 log10 against the BKV-specific genotype). Based on NAb titers on the day of transpla
Like
Comment
Share
